Highly Fragmented Market Necessitating Adoption of Unique Strategies

The contract pharmaceutical services manufacturing market is fairly fragmented, with manifold contract manufacturing organizations (CMOs) showing high dependence on limited number of clients. To gain a competitive edge in this highly fragmented market, contract pharmaceutical fermentation services’ providers are creating unique strategies based on prevailing pharmaceutical industry landscape and trends.

Read Report Overview: https://www.factmr.com/report/1517/contract-pharmaceutical-fermentation-services-market

To capitalize on the growing trend of pharmaceutical companies avoiding internal capacity investment to embrace outsourcing, contract pharmaceutical fermentation services’ providers continue to embed advancing technology in their processes. Further, several contract pharmaceutical fermentation services providers are indulging into collaborations with local integrators. To move ahead of the competition in contract pharmaceutical fermentation services market, leading players are focusing on extending and diversifying their businesses, as pharmaceutical industries turn to outsourcing to CMOs to underpin gains.

• January 2019 – A leading player in contract pharmaceutical fermentation services market, AbbVie, has collaborated with a privately held immunotherapy firm, Tizona Therapeutics, to manufacture and commercialize CD39-targeted therapeutics, such as TTX-030, an antibody for treating cancer.

Ask an Analyst : https://www.factmr.com/connectus/sample?flag=AE&rep_id=1517

• March 2018 – AbbVie, Inc. won Life Science Leader CMO award for contract manufacturing and reinforced its position in contract pharmaceutical fermentation services market.
• January 2019 – Another leading player in contract pharmaceutical fermentation services market, Boehringer Ingelheim International GmbH announced commencement of its capacity expansion at the company’s commercial manufacturing site for biologics located in China.
• December 2018 – Lonza announced plans about establishing a bio manufacturing base in China. Lonza has inked an agreement with GE Healthcare under which GE Healthcare will provide a biologics facility to a site in Guangzhou. The base is anticipated to be functional in 2020.

Get the Discount on the Report: https://www.factmr.com/connectus/sample?flag=D&rep_id=1517

Detailed profiles of other leading market players operating in contract pharmaceutical fermentation services market have also been included in contract pharmaceutical fermentation services market report. Key players operating in contract pharmaceutical fermentation services market include AbbVie, Inc., Aumgene Biosciences, EKF Diagnostics-Stanbio, Boehringer Ingelheim International GmbH, Biocon, AMRI, Pfizer, Lonza, CordenPharma International, and Fujifilm Holdings Corporation.